Latest Updates

Posts total revenue growth of 24.8 per cent at Rs 2023 million

Net sales up 18 per cent; EBITDA up 42 per cent and net profit up 40 per cent

EBITDA margin reported at 8.3 per cent

Expects to generate a revenue of $5 million within three years of the launch

Helps in reducing health hazards and also increasing safety of consumers

PBT up 52 per cent at Rs 80.49 crores

The consolidated revenue for the quarter ended September 30 was Rs 1197 crore

Amlodipine Besylate tablets is indicated for the treatment of hypertension, to lower blood pressure

EBITDA reported at Rs 362 crores; PAT at Rs 196 crores

Event orgnaised in collaboration with JSS university